Officials said two University of Mississippi students were found dead at or near campus, and that packaged kratom was recovered at both locations. Investigators have not determined a cause of death for either student, and the investigation is ongoing. Nothing below states or implies what caused these deaths. What follows is general information about kratom, the newer concentrated compounds sold alongside it, and what a standard drug test panel can and cannot detect, along with guidance for parents, colleges and employers.
What has been reported so far
Public statements from officials describe two facts only: two students were found dead at or near campus, and packaged kratom was found where each was located. Officials have not attributed either death to kratom, to any other substance, or to a combination of substances. Toxicology and medical examiner findings, when they are released, are the only source that can establish a cause of death. Any other claim, including claims that circulate on social media in the days after a campus death, is speculation and should be treated as such.
What kratom is
Kratom comes from the leaves of Mitragyna speciosa, a tree native to Southeast Asia. Products made from the leaf, including powders, capsules and extracts, are sold in convenience stores, smoke shops and online. According to the Food and Drug Administration, kratom is not lawfully marketed in the United States as a drug product, a dietary supplement, or a food additive, and the agency has not approved any kratom product for any medical use. The plant contains two compounds of particular interest to regulators: mitragynine and 7-hydroxymitragynine, commonly shortened to 7-OH. Both act on opioid receptors, and both are described by the National Institute on Drug Abuse as carrying risks that include dependence, withdrawal and, at higher exposures, respiratory depression, the same mechanism that makes opioid overdose dangerous.
Kratom leaf products and concentrated 7-OH products are not the same thing, and the distinction matters. Raw or lightly processed kratom leaf typically contains a small percentage of 7-OH relative to mitragynine. A newer category of product concentrates or synthesizes 7-OH to levels far above what occurs naturally in the plant, and sells it in tablets, gummies and shots marketed for pain relief or as an alternative to prescription opioids. The FDA's public health page on kratom discusses both the botanical product and these concentrated 7-OH products separately, and links to the agency's warning about concentrated 7-OH items sold "hiding in plain sight" in retail packaging that does not disclose the concentration.
Why concentrated 7-OH is drawing federal action
In a public health action, the FDA announced steps to restrict 7-OH opioid products, warning health care professionals and consumers about the risks of concentrated 7-OH sold as a legal alternative to prescription opioids. The full announcement is available from the FDA newsroom. Following that action, the Drug Enforcement Administration published a notice of intent to place 7-hydroxymitragynine above a specified threshold into Schedule I of the Controlled Substances Act, a filing that can be read in full on the Federal Register. None of this federal activity is a statement about the Ole Miss case. It reflects a broader concern that concentrated 7-OH products behave more like a manufactured opioid than a traditional botanical supplement, and that most buyers cannot tell from the label how much 7-OH a product actually contains.
A separate and newer risk: synthetic opioids sold under unfamiliar names
Apart from kratom and 7-OH, recent federal drug scheduling activity has focused on a wave of novel synthetic opioids, structurally related to older schedule I opioids, that have shown up in forensic seizures under names most people have never heard, including cychlorphine. This is a distinct and separate topic from the Ole Miss case and is included here only as general background on why campus and workplace risk from unregulated substances is rising, not as a statement about what was found in Mississippi. According to a Federal Register notice on international drug scheduling, cychlorphine had been confirmed in law enforcement seizures across multiple states and associated with fatalities in multiple states, with the DEA moving first to a notice of intent and then to a temporary final order placing cychlorphine, along with several related substances, into Schedule I. Both the notice of intent and the final scheduling order are public. The point for parents and employers is not this one compound. It is that new synthetic opioids keep appearing under names that mean nothing to the average buyer, and that a product bought as one thing can legally and chemically be something else entirely.
What a standard drug test panel actually screens for
This is where a lot of confusion happens, on campus and in the workplace. A standard 5, 10 or 12 panel screen was built around a specific list of substances, and kratom is generally not one of them unless the panel is built to include it.
| Substance | On a standard 5/10/12 panel | What actually detects it |
|---|---|---|
| Mitragynine (kratom) | Not included | A dedicated KRA strip or cup panel, or lab confirmation |
| 7-hydroxymitragynine (7-OH) | Not included on rapid panels | Lab based LC-MS/MS confirmation testing |
| Cychlorphine and other novel synthetic opioids | Not included on rapid panels | Lab based LC-MS/MS confirmation testing, targeted to the specific analyte |
| Fentanyl | Only if the panel specifically includes a fentanyl (FEN) strip | Fentanyl specific rapid strip, confirmed by lab testing |
| Traditional opiates (morphine, codeine) | Included on most standard panels | Standard immunoassay, confirmed by lab testing |
A negative result on a standard cup or a generic multi drug panel does not mean kratom, 7-OH, fentanyl or a novel synthetic opioid was absent. It means the panel was not built to look for it. Programs that want visibility into kratom use need a cup, dip card or oral fluid device with a dedicated KRA strip added to the configuration, and programs concerned about fentanyl exposure need a dedicated fentanyl strip, since neither compound is part of the traditional federal five or the common expanded panels by default. For anything beyond a rapid screen, including 7-OH and emerging synthetics like cychlorphine, the only reliable route is laboratory confirmation, and the ordering party should ask the lab directly which analytes its confirmation test actually reports, since not every lab panel covers every emerging compound.
What parents can say to students
Parents do not need to diagnose anything to have a useful conversation. A few points are worth making plainly: products sold as kratom, or as a "legal" pain reliever or energy supplement, are not reviewed or approved by the FDA the way a prescription drug is, so nobody outside the seller knows what is actually in the package or at what strength. Concentrated 7-OH products can act more like an opioid than a plant supplement, and mixing any opioid acting substance with alcohol, sedatives or other depressants increases the risk of slowed or stopped breathing. If a friend is unresponsive, breathing slowly, or cannot be woken, that is a medical emergency and campus emergency services should be called immediately. None of this requires knowing what specifically caused the Ole Miss deaths, because the general safety message stands regardless of that outcome.
What colleges and employers with safety sensitive roles can do lawfully
Colleges are not employers and most student conduct is not governed by workplace drug testing law, but the operational lessons overlap for any employer running a drug free workplace program, particularly in safety sensitive roles such as transportation, health care, manufacturing or campus public safety.
- Set policy before an incident, not after. A written policy should say plainly whether kratom and other legal but unregulated substances are covered, and what panel configuration the program actually uses.
- Choose the panel deliberately. If kratom or fentanyl exposure is a real concern for the population being tested, the panel needs a dedicated KRA or fentanyl strip added, not assumed to already be part of a standard configuration.
- Use lab confirmation for anything a rapid panel cannot resolve. Emerging compounds like 7-OH and novel synthetic opioids require LC-MS/MS confirmation, not a rapid strip alone.
- Route people to help, not just enforcement. An employee assistance program or campus counseling referral is appropriate whenever a substance use concern surfaces, and general information on substance use disorder and treatment options is available through the Substance Abuse and Mental Health Services Administration.
- Never treat a screening result as a diagnosis. A positive screen is presumptive. A medical review officer should review any positive result and give the individual a chance to provide a legitimate medical explanation before any employment action is taken.
- Consult counsel on discipline decisions. Employers generally may act on a verified positive result under a lawful, consistently applied policy, but the details depend on state law, union agreements and the specific substance involved, so legal counsel should review any adverse action.
Frequently asked questions
Does a standard drug test detect kratom?
Not automatically. A standard 5, 10 or 12 panel test generally does not include kratom unless a dedicated KRA (mitragynine) strip has been added to the cup, dip card or oral fluid device.
Can 7-OH or cychlorphine show up on a rapid drug test?
No. Neither 7-hydroxymitragynine nor newer synthetic opioids such as cychlorphine are included on standard rapid immunoassay panels. Detecting them requires laboratory based LC-MS/MS confirmation testing targeted to those specific compounds.
Is kratom illegal?
Kratom's legal status varies by state and locality, and some jurisdictions restrict or ban its sale. At the federal level, the FDA has not approved kratom for any medical use and states it is not lawfully marketed as a dietary supplement, while the DEA has moved to place concentrated 7-hydroxymitragynine into Schedule I. Anyone with a specific legal question should check current state and local law directly.
Has kratom been confirmed as the cause of the Ole Miss student deaths?
No. Officials have said packaged kratom was recovered at both locations, but causes of death have not been determined and the investigation is ongoing. No official source has attributed either death to kratom or to any other specific substance.
What should an employer do if it wants to screen for kratom or fentanyl?
Add a dedicated KRA strip for kratom and a dedicated fentanyl strip to the test configuration, since neither is part of most standard panels by default, and confirm any positive or unresolved result through a laboratory rather than relying on the rapid screen alone.
What is the medical review officer's role in a positive test result?
A medical review officer reviews any positive laboratory confirmed result, gives the tested individual an opportunity to provide a legitimate medical explanation such as a valid prescription, and only then reports a verified result to the employer.
For programs that need to add kratom or fentanyl detection to an existing testing configuration, American Screening Corporation supplies drug test cups that can be configured with a dedicated KRA strip, along with related panels covered in more detail in our posts on 7-OH and kratom screening and on synthetic opioids that standard panels miss.
This article is general information only and is not legal or medical advice. Employers should consult qualified counsel before adopting or enforcing a drug testing policy, and anyone concerned about their own or another person's substance use should contact a medical professional or a crisis service.